<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835716</url>
  </required_header>
  <id_info>
    <org_study_id>PCD=OO ALZ</org_study_id>
    <nct_id>NCT02835716</nct_id>
  </id_info>
  <brief_title>Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO</brief_title>
  <acronym>PCD=OOALZ</acronym>
  <official_title>Pre-Clinical Alzheimer's (ALZ) Diagnosis (PCD) = Optimum Outcomes (OO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Magnetic Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Magnetic Technologies, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Observational protocol will attempt to verify two recent and very critical concepts in
      ALZ Clinical Research by studying high-risk individuals who already are taking medications
      which may prevent the onset of ALZ.

        -  It may be possible to determine the future development of ALZ in a preclinical state in
           a cognitively normal but high risk individual at least 18-24 months before any symptoms
           develop of cognitive impairment.

        -  Early treatment of these cognitively normal high-risk persons with subclinical pre-ALZ
           can prevent of delay the occurrence and severity of ALZ.

      Caveats

      Neither this protocol nor the fMRI imaging are designed or intended to diagnose or treat ALZ,
      nor develop or use medications or diagnostic neuroimaging outside of already approved and
      accepted parameters. Persons who volunteer to be study subjects in this observational
      protocol will be under the care of their primary care / specialty physician, who will order
      tests and treatments as they see appropriate.

      Although there is a very large body of peer-reviewed scientific literature demonstrating that
      certain functional MRI patterns are associated with certain neurologic conditions, the
      utilization of fMRI for the evaluation of neurologic disorders is still considered an
      emerging science and therefore in the investigational stage. Although this protocol will
      report on brain patterns of certain neurologic conditions such as cognitive impairment and
      Alzheimer's disease, based on patterns published in peer-reviewed journals, such findings are
      not considered stand alone or diagnostic per se and should always be considered by the PMD in
      conjunction with the patient's clinical condition. These data should only be used as
      additional information to add to the PMD's diagnostic impression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective observational study participants age 50-75 years are identified who are currently
      (&lt;1 month) taking or will soon (within 3 months) start taking study medications of interest
      thru their own physician.

      Prospective observational study participants are explained how persons can be cognitively
      normal but at high risk for developing clinical ALZ, and that this risk can be prospectively
      identified.

      They are advised that there is some rationale that medications they are or will soon be
      taking may have a protective effect in delaying the onset of ALZ, and that protective effect
      can be monitored.

      They are asked if they would like to participate in a protocol that monitors their
      prospective risk for developing ALZ short term, and whether certain of their prescribed
      medications may have a protective effect. Those who are accepting to be participants are then
      enrolled in the study.

      Enrollees are tested for risk factors for having pre-clinical ALZ. Individuals identified as
      being at risk at baseline are followed at 6 month intervals for a 24 month period using
      psychometric testing and functional neuroimaging. Their maintenance of cognitive stability or
      cognitive decline is monitored while under the care of their PMD and while taking medications
      of interest.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of Participants who Develop Cognitive Decline</measure>
    <time_frame>18-24 month</time_frame>
    <description>Cognitive decline is defined as a reduction from baseline performance within each individual of at least one standard deviation (SD) on at least one of the three principal outcome indices (DRS-2, RAVLT Sum of Trials 1-5 [T1- 5], RAVLT Delayed Recall [DR]).</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roflumilast</intervention_name>
    <description>DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations</description>
    <other_name>Daliresp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ustekinumab</intervention_name>
    <description>STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body</description>
    <other_name>Stelara</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults at high risk of developing ALZ within 18-48 months but are currently cognitively
        normal for their age sex matching group. Risk factors include parents with a history of
        ALZ, and/or positive APOE4 alleles.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 to 75 years old,

          -  Normal baseline cognitive function by standard psychometric testing.

          -  Able to privately fund psychometric and neuroimaging studies if not covered by their
             insurance,

          -  Able to give written Informed Consent,

          -  Ascent for collaboration by their primary care or specialty physician,

          -  Currently taking (&lt;1 month) or planning to take (within the next 3 months) medications
             which are identified in the study group of interest, prescribed by and under the care
             of a PMD or specialty physician.

        Exclusion Criteria:

        • Inability to undergo MR Imaging : Claustrophobia, certain metal implants,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald H Marks, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MMT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donald H Marks, MD PhD</last_name>
    <phone>9733070364</phone>
    <email>DHM@MilMag.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steve Levy, MD</last_name>
    <phone>2034239494</phone>
    <email>SL@MilMag.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Millennium Magnetic Technologies, LLC</name>
      <address>
        <city>Westport</city>
        <state>Connecticut</state>
        <zip>06880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Levy, MD</last_name>
      <phone>203-423-9494</phone>
      <email>SL@MilMag.net</email>
    </contact>
    <contact_backup>
      <last_name>Donald H Marks, MD PhD</last_name>
      <phone>9733070364</phone>
      <email>DHM@MilMag.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://print.ispub.com/api/0/ispub-article/7521</url>
    <description>Multidimensional Representation of Concepts as Cognitive Engrams in the Human Brain</description>
  </link>
  <link>
    <url>http://ispub.com/IJH/8/1/9567</url>
    <description>Evaluation of Cognitive Impairment</description>
  </link>
  <link>
    <url>https://pharmaceuticalintelligence.com/2013/02/27/ustekinumab-new-drug-therapy-for-cognitive-decline-resulting-from-neuroinflammatory-cytokine-signaling-and-alzheimers-disease/</url>
    <description>Ustekinumab New Drug Therapy for Cognitive Decline resulting from Neuroinflammatory Cytokine Signaling and Alzheimer's Disease</description>
  </link>
  <link>
    <url>http://www.blisstree.com/2012/11/28/sex-relationships/psoriasis-drug-fights-alzheimers-by-treating-it-like-an-auto-immune-disease/</url>
    <description>Psoriasis Drug Fights Alzheimer's By Treating It Like An Auto-Immune Disease Read more: http://www.blisstree.com/2012/11/28/sex-relationships/psoriasis-drug-fights-alzheimers-by-treating-it-like-an-auto-immune-disease/#ixzz4E2UkfKgm</description>
  </link>
  <reference>
    <citation>Bangen KJ, Restom K, Liu TT, Wierenga CE, Jak AJ, Salmon DP, Bondi MW. Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study. J Alzheimers Dis. 2012;31 Suppl 3:S59-74.</citation>
    <PMID>22531427</PMID>
  </reference>
  <reference>
    <citation>Caltagirone C, Ferrannini L, Marchionni N, Nappi G, Scapagnini G, Trabucchi M. The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review. Aging Clin Exp Res. 2012 Dec;24(6):580-7. doi: 10.3275/8585. Epub 2012 Sep 5. Review.</citation>
    <PMID>22961121</PMID>
  </reference>
  <reference>
    <citation>Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR Jr, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis. 2014 Dec;1(3):181-202.</citation>
    <PMID>26478889</PMID>
  </reference>
  <reference>
    <citation>Chincarini A, Bosco P, Calvini P, Gemme G, Esposito M, Olivieri C, Rei L, Squarcia S, Rodriguez G, Bellotti R, Cerello P, De Mitri I, Retico A, Nobili F; Alzheimer's Disease Neuroimaging Initiative. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. Neuroimage. 2011 Sep 15;58(2):469-80. doi: 10.1016/j.neuroimage.2011.05.083. Epub 2011 Jun 16.</citation>
    <PMID>21718788</PMID>
  </reference>
  <reference>
    <citation>Chiang K, Koo EH. Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2014;54:381-405. doi: 10.1146/annurev-pharmtox-011613-135932. Review.</citation>
    <PMID>24392696</PMID>
  </reference>
  <reference>
    <citation>Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):94-7. doi: 10.1097/WAD.0b013e31815a9dcc.</citation>
    <PMID>18317253</PMID>
  </reference>
  <reference>
    <citation>Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother. 2017 Jan;17(1):17-32. Epub 2016 Jun 24.</citation>
    <PMID>27293026</PMID>
  </reference>
  <reference>
    <citation>García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci. 2012 Nov 21;3(11):832-44. doi: 10.1021/cn3000907. Epub 2012 Oct 1. Review.</citation>
    <PMID>23173065</PMID>
  </reference>
  <reference>
    <citation>Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'. J Intern Med. 2016 Jun;279(6):576-91. doi: 10.1111/joim.12482. Epub 2016 Mar 4.</citation>
    <PMID>26940242</PMID>
  </reference>
  <reference>
    <citation>Griffin WS. Neuroinflammatory cytokine signaling and Alzheimer's disease. N Engl J Med. 2013 Feb 21;368(8):770-1. doi: 10.1056/NEJMcibr1214546.</citation>
    <PMID>23425171</PMID>
  </reference>
  <reference>
    <citation>Gurney ME, D'Amato EC, Burgin AB. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. Neurotherapeutics. 2015 Jan;12(1):49-56. doi: 10.1007/s13311-014-0309-7. Review.</citation>
    <PMID>25371167</PMID>
  </reference>
  <reference>
    <citation>Christensen KD, Roberts JS, Whitehouse PJ, Royal CD, Obisesan TO, Cupples LA, Vernarelli JA, Bhatt DL, Linnenbringer E, Butson MB, Fasaye GA, Uhlmann WR, Hiraki S, Wang N, Cook-Deegan R, Green RC; REVEAL Study Group*. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med. 2016 Feb 2;164(3):155-63. doi: 10.7326/M15-0187. Epub 2016 Jan 26.</citation>
    <PMID>26810768</PMID>
  </reference>
  <reference>
    <citation>Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, Obisesan TO, Cook-Deegan R, Linnenbringer E, Butson MB, Fasaye GA, Levinson E, Roberts JS; REVEAL Study Group. A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement. 2015 Oct;11(10):1222-30. doi: 10.1016/j.jalz.2014.10.014. Epub 2014 Dec 9.</citation>
    <PMID>25499536</PMID>
  </reference>
  <reference>
    <citation>Haller S, Nguyen D, Rodriguez C, Emch J, Gold G, Bartsch A, Lovblad KO, Giannakopoulos P. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis. 2010;22(1):315-27. doi: 10.3233/JAD-2010-100840.</citation>
    <PMID>20847435</PMID>
  </reference>
  <reference>
    <citation>Heckman PR, Wouters C, Prickaerts J. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr Pharm Des. 2015;21(3):317-31. Review.</citation>
    <PMID>25159073</PMID>
  </reference>
  <reference>
    <citation>Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010 Jan 12;340:b5465. doi: 10.1136/bmj.b5465.</citation>
    <PMID>20068258</PMID>
  </reference>
  <reference>
    <citation>Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013 Jul;9(7):371-81. doi: 10.1038/nrneurol.2013.107. Epub 2013 Jun 11. Review. Erratum in: Nat Rev Neurol. 2013 Aug;9(8):418.</citation>
    <PMID>23752908</PMID>
  </reference>
  <reference>
    <citation>Lazarczyk MJ, Hof PR, Bouras C, Giannakopoulos P. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med. 2012 Oct 25;10:127. doi: 10.1186/1741-7015-10-127. Review.</citation>
    <PMID>23098093</PMID>
  </reference>
  <reference>
    <citation>Peters KR, Lynn Beattie B, Feldman HH, Illes J. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. Prog Neurobiol. 2013 Nov;110:114-23. doi: 10.1016/j.pneurobio.2012.12.001. Epub 2013 Jan 21. Review.</citation>
    <PMID>23348495</PMID>
  </reference>
  <reference>
    <citation>Riedel WJ. Preventing cognitive decline in preclinical Alzheimer's disease. Curr Opin Pharmacol. 2014 Feb;14:18-22. doi: 10.1016/j.coph.2013.10.002. Epub 2013 Nov 13. Review.</citation>
    <PMID>24565007</PMID>
  </reference>
  <reference>
    <citation>Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013 Sep 9;8(9):e74062. doi: 10.1371/journal.pone.0074062. eCollection 2013.</citation>
    <PMID>24040166</PMID>
  </reference>
  <reference>
    <citation>Zhou Y, Tan C, Wen D, Sun H, Han W, Xu Y. The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging. Front Aging Neurosci. 2016 Apr 27;8:92. doi: 10.3389/fnagi.2016.00092. eCollection 2016.</citation>
    <PMID>27199739</PMID>
  </reference>
  <reference>
    <citation>Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr. 2010 May;91(5):1402-7. doi: 10.3945/ajcn.2009.28981. Epub 2010 Mar 10.</citation>
    <PMID>20219963</PMID>
  </reference>
  <reference>
    <citation>Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, Lopategui-Cabezas I, Wegner A, Mair F, Schipke CG, Peters O, Winter Y, Becher B, Heppner FL. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med. 2012 Dec;18(12):1812-9. doi: 10.1038/nm.2965. Epub 2012 Nov 25.</citation>
    <PMID>23178247</PMID>
  </reference>
  <reference>
    <citation>Woodard JL, Seidenberg M, Nielson KA, Smith JC, Antuono P, Durgerian S, Guidotti L, Zhang Q, Butts A, Hantke N, Lancaster M, Rao SM. Prediction of cognitive decline in healthy older adults using fMRI. J Alzheimers Dis. 2010;21(3):871-85. doi: 10.3233/JAD-2010-091693.</citation>
    <PMID>20634590</PMID>
  </reference>
  <reference>
    <citation>Xekardaki A, Rodriguez C, Montandon ML, Toma S, Tombeur E, Herrmann FR, Zekry D, Lovblad KO, Barkhof F, Giannakopoulos P, Haller S. Arterial spin labeling may contribute to the prediction of cognitive deterioration in healthy elderly individuals. Radiology. 2015 Feb;274(2):490-9. doi: 10.1148/radiol.14140680. Epub 2014 Oct 7.</citation>
    <PMID>25291458</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>September 10, 2016</last_update_submitted>
  <last_update_submitted_qc>September 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphodiesterase type 4 inhibitor</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>secukinumab</keyword>
  <keyword>P40 subunit</keyword>
  <keyword>Interleukin IL-12</keyword>
  <keyword>Interleukin IL-23</keyword>
  <keyword>Apoprotein e4</keyword>
  <keyword>Interleukin IL-17A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

